Smithfield Trust’s Agios Pharmaceuticals AGIO Stock Holding History

Smithfield Trust’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-15	Closed	-$1K	–	1085
2020 Q2	$1K	Buy	+15	New	+$695	﹤0.01%	1000

Other funds holding AGIO

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Smithfield Trust's AGIO Position: Q3 2020 in Review

Smithfield Trust sold out of Agios Pharmaceuticals (AGIO) in Q3 2020, closing a stake of 15 shares — an estimated $1K sold.

Smithfield Trust first reported a position in AGIO in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 214 funds tracked by Wall St. Rank hold AGIO as of Q3 2020.

Smithfield Trust reported no remaining Agios Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Smithfield Trust sold 15 Agios Pharmaceuticals shares in Q3 2020, an estimated $1K.
Smithfield Trust first reported a position in Agios Pharmaceuticals in Q2 2020 and held it in 1 quarter.
Smithfield Trust's Agios Pharmaceuticals position peaked at $1K in Q2 2020.
214 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2020.

Based on Smithfield Trust's 13F filing for Q3 2020, filed 16 Nov 2020.